Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | PRKCA | P17252 | 10/20 | 0.84 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.80 |
| ▸ | PRKCG | P05129 | 1/20 | 0.80 |
| ▸ | PRKCB | P05771 | 1/20 | 0.80 |
| ▸ | PRKCH | P24723 | 1/20 | 0.80 |
| ▸ | PRKCI | P41743 | 1/20 | 0.80 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.80 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.80 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.80 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.80 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.80 |
| ▸ | TOP1 | P11387 | 12/20 | 0.62 |
| ▸ | EGFR | P00533 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rebeccamycin SCHEMBL12961242 | 1.00 | DYRK1A (1.00) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| Rebeccamycin SCHEMBL32690193 | 1.00 | DYRK1A (1.00) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| Rebeccamycin SCHEMBL14069957 | 1.00 | DYRK1A (1.00) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| Rebeccamycin SCHEMBL30194716 | 1.00 | DYRK1A (1.00) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| SCHEMBL10027492 | 0.89 | DYRK1A (0.81) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| SCHEMBL7165791 | 0.86 | DYRK1A (0.76) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| Rebeccamycin SCHEMBL19100060 | 0.86 | DYRK1A (0.75) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| Becatecarin SCHEMBL5953787 | 0.85 | PRKCA (0.78) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| Becatecarin SCHEMBL5953888 | 0.85 | PRKCA (0.78) | DYRK1APAX8PRKCAPRKD3PRKCG | |
| Becatecarin SCHEMBL31237559 | 0.85 | PRKCA (0.78) | DYRK1APAX8PRKCAPRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6055 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731263-A1 | BIO-CONJUGATES FOR ONCOLOGY | RDP Pharma AG (CH) | 2026-04-29 | — | — | EP | claimed |
| EP-4673458-A1 | METHODS OF ENHANCING PRODUCTION OF METABOLITES IN BACTERIA | JOHN INNES CENTRE (GB) | 2026-01-07 | — | — | EP | claimed |
| US-20250325717-A1 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-23 | — | — | US | claimed |
| US-20250313647-A1 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-09 | — | — | US | claimed |
| US-20250304688-A1 | Methods and Compositions Comprising Anti-CD3 Antibodies and DYRK1A Inhibitors for Treating Diabetes | PROVENTION BIO, INC. (US) | 2025-10-02 | — | — | US | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| EP-4580677-A2 | SARS-COV2 ANTIBODIES AND USES THEREOF | Invivyd, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| EP-4514857-A2 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | The Children's Medical Center Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4514858-A2 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | The Children's Medical Center Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4505179-A2 | SARS-COV2 ANTIBODIES AND USES THEREOF | Invivyd, Inc. (US) | 2025-02-12 | — | — | EP | claimed |
| US-5468849-A | Rebeccamycin analogs by tryptophan analogs feeding | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-21 | — | — | US | claimed |
| EP-0269025-B1 | REBECCAMYCIN ANALOGS | Bristol-Myers Squibb Company (US) | 1993-01-13 | — | — | EP | claimed |
| EP-0450327-A1 | Biosynthesis of rebeccamycin analogs by tryptophan analogs feeding | Bristol-Myers Squibb Company (US) | 1991-10-09 | — | — | EP | claimed |
| EP-0445736-A1 | Rebeccamycin analog and pharmaceutical composition containing it | Bristol-Myers Squibb Company (US) | 1991-09-11 | — | — | EP | claimed |
| CN-1047204-A | Stabilizing solution of rebeccamycin analog and preparation method thereof | BRISTOL MYERS SQUIBB CO (US) | 1990-11-28 | — | — | CN | claimed |
| EP-0115350-B1 | REBECCAMYCIN AND PROCESS FOR ITS PREPARATION | Bristol-Myers Company (US) | 1988-08-17 | — | — | EP | claimed |
| EP-0269025-A2 | Rebeccamycin analogs | Bristol-Myers Squibb Company (US) | 1988-06-01 | — | — | EP | claimed |
| US-4552842-A | ANTITUMOR AGENTS | BRISTOL-MYERS COMPANY (US) | 1985-11-12 | — | — | US | claimed |
| US-4487925-A | ANTITUMOR AGENT | BRISTOL-MYERS COMPANY (US) | 1984-12-11 | — | — | US | claimed |
| EP-0115350-A2 | Rebeccamycin and process for its preparation | Bristol-Myers Company (US) | 1984-08-08 | — | — | EP | claimed |